Conversely, in pulmonary fibrosis, selpercatinib inhibits fibroblast proliferation, migration, activation, and ECM deposition by suppressing the TGF-β/Smad pathway, thereby attenuating the progression of lung fibrosis (9). Here, TGFB1 is linked to pulmonary fibrosis.